Present and future therapeutic strategies in non-alcoholic fatty liver disease.
about
Probiotics for patients with hepatic encephalopathyCurcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signalingCurcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2Liver glycerol permeability and aquaporin-9 are dysregulated in a murine model of Non-Alcoholic Fatty Liver Disease.Adiponectin, a key adipokine in obesity related liver diseasesExperimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in ratsSexual Dimorphism of Adipose and Hepatic Aquaglyceroporins in Health and Metabolic Disorders.Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stressCombined ethanol extract of grape pomace and omija fruit ameliorates adipogenesis, hepatic steatosis, and inflammation in diet-induced obese mice.The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.Participation of aquaporin-1 in vascular changes and remodeling in cirrhotic liver.Altered distribution of caveolin-1 in early liver steatosis.Mechanisms and clinical implications of hepatocyte lipoapoptosis.Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro.Management of liver cirrhosis between primary care and specialists.Dmbt1 does not affect a Western style diet-induced liver damage in mice.Reduced hepatic aquaporin-9 and glycerol permeability are related to insulin resistance in non-alcoholic fatty liver disease.Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease.
P2860
Q24235259-BAF94574-59B4-4321-9385-5973E288EDCEQ34409300-44F76D54-1A31-493B-A9F1-C2B923302CECQ34574662-9C7B86EB-FE80-49B5-9B45-01E4E9D214D0Q35036094-F51D2A9B-2607-4B3D-B49B-B7D8F8BC21E5Q35061908-FA3E407E-B8B4-490F-8571-52E2EE8C0765Q35601541-27D8038F-D7EE-4988-B409-31DD4FC783A0Q36216714-2C683BD4-2DCD-4E22-ABFE-6B584C2432CBQ36249410-23ED9377-65F1-4160-918D-EB6FAB64045BQ36252773-BB4385AF-B70D-4A29-A04E-0DB42FD7E274Q36838159-A52DE39F-771D-463A-9E39-A1EEB1158078Q36954679-4552EA7C-BA24-49AF-AD32-6A9C852DE190Q38095400-5CB05165-C81C-40EE-851F-5B9D44E42B2AQ39791849-E9E34282-A57A-4F9B-B2F6-7049BB0B1C56Q39845029-92ED87B1-2804-4E6F-B977-02FAD701E9D2Q42182823-090EEE96-D9D8-4F91-9367-0A65B09F750EQ42736692-1EB9DC3D-F551-499F-BADA-AF9ED4E8C245Q42920900-18A35F38-C1CB-49BF-9B6F-2149C61ACD87Q43678877-B069CA88-11B9-431A-93FC-B425E36BB8F9Q53098897-9CBDA461-84A1-4E81-A365-79F3B3DA4A96
P2860
Present and future therapeutic strategies in non-alcoholic fatty liver disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Present and future therapeutic strategies in non-alcoholic fatty liver disease.
@en
type
label
Present and future therapeutic strategies in non-alcoholic fatty liver disease.
@en
prefLabel
Present and future therapeutic strategies in non-alcoholic fatty liver disease.
@en
P2860
P1476
Present and future therapeutic strategies in non-alcoholic fatty liver disease.
@en
P2093
Giuseppe Calamita
Piero Portincasa
P2860
P304
P356
10.1517/14728222.11.9.1231
P407
P577
2007-09-01T00:00:00Z